AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful combination ...
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...
AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
Discover the latest April 2025 update on Dow Dogs! Learn about top investment picks, forecasted gains, and market corrections ...
Learn more about whether Jazz Pharmaceuticals plc or Merck & Co., Inc. is a better investment based on AAII's A+ Investor ...
In high-risk patients with pulmonary arterial hypertension, Merck ’s fusion protein therapeutic Winrevair reduced the ...
With the CSF-1R inhibitor space heating up, Germany's Merck Group has gone all-in on pimicotinib, paying Abbisko Therapeutics ...
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and ...
Communication between health-care professionals and individuals with cancer regarding the effects of treatment on sexual ...
The Hatch-Waxman Act seeks to strike a balance in the pharmaceutical industry by incentivizing drugs makers to develop ...
AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...
In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension ...